Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest hopes for 2011 approval of Daxas

This article was originally published in Scrip

Executive Summary

Forest Laboratories says it has addressed concerns raised in a US FDA complete response letter about lung drug Daxas (roflumilast). Forest says the FDA has acknowledged receipt of the resubmission, and the company expects a response from the agency in the first quarter of 2011.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC010152

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel